%0 Journal Article
%A Lanzafame, Helena
%A Mavroeidi, Ilektra A
%A Pabst, Kim M
%A Fragoso Costa, Pedro
%A Schuler, Martin
%A Bauer, Sebastian
%A Kurth, Jens
%A Heuschkel, Martin
%A Siveke, Jens T
%A Herrmann, Ken
%A Kostbade, Karina
%A Kersting, David
%A Leyser, Stephan
%A Fröhling, Stefan
%A Heilig, Christoph E
%A Hamacher, Rainer
%A Fendler, Wolfgang P
%T 90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis.
%J Journal of nuclear medicine
%V nn
%@ 0097-9058
%C New York, NY
%I Soc.
%M DKFZ-2026-00406
%P nn
%D 2026
%Z epub
%X Fibroblast activation protein (FAP) is highly expressed in many cancers, especially sarcomas, and represents a promising theranostic target. We present an updated retrospective analysis of 90Y-FAP inhibitor (FAPI)-46 treatment in patients with sarcoma or other solid tumors. Methods: We performed monocentric analysis of patients with progressive sarcoma or metastatic cancer who were eligible for 90Y-FAPI-46 therapy after approved treatments had been exhausted and who showed high FAP expression (SUVmax, ≥10 in over 50
%K 90Y-FAPI-46 (Other)
%K radiopharmaceutical therapy (Other)
%K sarcomas (Other)
%K theranostics (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41714122
%R 10.2967/jnumed.125.271135
%U https://inrepo02.dkfz.de/record/309980